大多数季度计划失败于产能算术，而非优先级选择，前提是已在38,000名归属生命上接受了下行风险。 医疗服务提供者的难点在于结构：已在38,000名生命上接受下行风险，却缺少定价所需的分次成本数据。任何可信方案都必须同时把握分次成本与 payer mix，而这正是大部分内部分析止步之处，因为两者分属不同系统。
大多数季度计划失败于产能算术，而非优先级选择，前提是已在38,000名归属生命上接受了下行风险。 医疗服务提供者的难点在于结构：已在38,000名生命上接受下行风险，却缺少定价所需的分次成本数据。任何可信方案都必须同时把握分次成本与 payer mix，而这正是大部分内部分析止步之处，因为两者分属不同系统。
一个季度只有固定管理注意力与固定现金，大多数计划却同时透支两者。结果不是失败，而是无声筛选：组织只做了38,000名归属生命中力所能及的部分，没人记录哪些分次成本控制或 payer mix 调整被放弃。
能经得起实际执行的计划，按回报对候选动作排序，再用实际可用产能核对，最后排序使前一项为后一项提供资金或解锁。面板规模或每提供者贡献上的三项真实优先级，永远胜过十二项口头优先级。
几乎总是缺失的部分是停止规则——在分次成本或归属生命上设定的观察点，用来判断动作是否失效，且必须在启动前定义，而非事后争论。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 上季度基于价值的合同计划只完成一部分，却无人正式取消任何事项
✓ payer mix 或面板规模的优先级已列出，但未排序
✓ 没有任何分次成本举措写明失败条件
通常会让情况更糟的做法。 承诺所有看似重要的事，结果组织只能按便利自行选择。
It is for you if you run or finance a healthcare provider and last quarter's plan was partly done and nobody formally dropped anything. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供者. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Convert existing downside-risk scale into CMS-mandated quality infrastructure that locks in 48+ month structural durability.
The leak it closes. Binary default risk on $6.8M revenue eliminated through cost-per-episode analytics
The assumption it rests on. CMS continues ACO REACH program through 2030 — the engine put the probability at 0.85.
| Investment required | $225-325K total over 36 months ($75K regulatory consultant + $150-250K analytics tooling) |
| Expected return | 69.8× on $325K investment if ACO REACH approved — derived from $22.7M NPV upside / $325K investment |
| Revenue, year 1 | $0 incremental (application phase) |
| Revenue, year 2 | $1.0M incremental (0.5 point margin lift on $196M) |
| Revenue, year 3 | $2.0M incremental (1.0 point margin lift on $196M) |
| Exit criteria | Abandon if CMS terminates ACO REACH program OR physician ownership falls below 55% OR application rejected after two submissions |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 增长组合框架, one of 29 engagements the platform runs. For 医疗服务提供者 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
以实际产能为限，大多数中小企业的真实数字是两到三项。这是算术题，不是哲学题。
先按每项消耗的产能回报排序，再看可逆性。接近时选能停的那项。
这正是停止规则的作用。预先约定失败条件的计划，能按证据调整，而非靠争论，这是适应与漂移的区别。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית